Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

By H. Masuda, Keith A. Baggerly, Ying Wang, Ya Zhang, A. González-Angulo, Funda Meric-Bernstam, V. Valero, B. Lehmann, J. Pietenpol, G. Hortobagyi and 2 more. Clinical Cancer Research, 2013

668 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “Even across other studies in which TNBC was identified using mRNA expression, reproducibility of the BL2 and UNS subtypes has not been consistent (16, 17).”
Triple-negative breast cancer molecular subtyping and treatment progress (2020, methodology): “The pCR rate of the BL1 subtype was the highest (52%), while those of the BL2, LAR, and MSL subtypes were 0%, 10%, and 23%, respectively [18].”
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Further dissection of subtypes within triple-negative breast cancer reveals seven distinct groupings, which differ markedly in their clinical response to neoadjuvant chemotherapy [51].”